Relation of Patient Age and Mortality to Reported Contraindications to Early Beta-Blocker Use for Non-ST-Elevation Acute Coronary Syndrome

Nancy M. Allen LaPointe, Anita Y. Chen, Matthew T. Roe, David J. Cohen, Deborah B. Diercks, James W. Hoekstra, Francis M. Fesmire, W. Brian Gibler, E. Magnus Ohman, Eric D. Peterson

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We evaluated the reported contraindications to early β-blocker use and associated mortality within and across patient age groups. Contraindications to early β-blocker use were evaluated in patients with non-ST-elevation acute coronary syndrome in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) initiative from February 2003 to December 2006. The prevalence, reasons, and trends in the contraindications were evaluated by age (≤65, 66 to 74, and ≥75 years). The associations between the reported contraindications and in-hospital mortality were determined within and compared across age groups using the logistic generalized estimating equations method, adjusting for baseline patient characteristics. Of 112,448 patients, 11,711 (10.4%) had a reported contraindication to early β-blocker use. The prevalence varied by age (≤65, 7.9%; 66 to 74, 10.6%; and ≥75, 13.4%; p <0.0001). No significant changes were seen over time, except for a small increase in patients ≤65 years (p = 0.001). Among the hospitals with >40 patients in the registry, the median hospital level rate of reported contraindications was 9.9% (interquartile range 6.7% to 14.3%). The distribution of rates was more widespread among the hospitals' older versus younger patients. In all age groups, a statistically significant greater association was found with in-hospital mortality in those with reported contraindications versus those without contraindications who received a β blocker (adjusted odds ratio 2.81, 95% confidence interval 2.28 to 3.46; adjusted odds ratio 2.50, 95% confidence interval 2.07 to 3.03; adjusted odds ratio 2.11, 95% confidence interval 1.88 to 2.37, for ages ≤65, 66 to 74, and ≥75 years, respectively). The strength of the association was similar across all age groups (interaction p = 0.19). The reported contraindications to early β-blocker use were common and increased with age. The contraindications were independently associated with greater in-hospital mortality, underscoring the importance of accurately identifying contraindications. In conclusion, the results did not indicate any disparity in reporting the contraindications according to patient age.

Original languageEnglish (US)
Pages (from-to)1324-1329
Number of pages6
JournalAmerican Journal of Cardiology
Volume104
Issue number10
DOIs
StatePublished - Nov 15 2009

Fingerprint

Acute Coronary Syndrome
Mortality
Age Groups
Hospital Mortality
Odds Ratio
Confidence Intervals
Unstable Angina
Registries
Guidelines

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Allen LaPointe, N. M., Chen, A. Y., Roe, M. T., Cohen, D. J., Diercks, D. B., Hoekstra, J. W., ... Peterson, E. D. (2009). Relation of Patient Age and Mortality to Reported Contraindications to Early Beta-Blocker Use for Non-ST-Elevation Acute Coronary Syndrome. American Journal of Cardiology, 104(10), 1324-1329. https://doi.org/10.1016/j.amjcard.2009.06.054

Relation of Patient Age and Mortality to Reported Contraindications to Early Beta-Blocker Use for Non-ST-Elevation Acute Coronary Syndrome. / Allen LaPointe, Nancy M.; Chen, Anita Y.; Roe, Matthew T.; Cohen, David J.; Diercks, Deborah B.; Hoekstra, James W.; Fesmire, Francis M.; Gibler, W. Brian; Ohman, E. Magnus; Peterson, Eric D.

In: American Journal of Cardiology, Vol. 104, No. 10, 15.11.2009, p. 1324-1329.

Research output: Contribution to journalArticle

Allen LaPointe, NM, Chen, AY, Roe, MT, Cohen, DJ, Diercks, DB, Hoekstra, JW, Fesmire, FM, Gibler, WB, Ohman, EM & Peterson, ED 2009, 'Relation of Patient Age and Mortality to Reported Contraindications to Early Beta-Blocker Use for Non-ST-Elevation Acute Coronary Syndrome', American Journal of Cardiology, vol. 104, no. 10, pp. 1324-1329. https://doi.org/10.1016/j.amjcard.2009.06.054
Allen LaPointe, Nancy M. ; Chen, Anita Y. ; Roe, Matthew T. ; Cohen, David J. ; Diercks, Deborah B. ; Hoekstra, James W. ; Fesmire, Francis M. ; Gibler, W. Brian ; Ohman, E. Magnus ; Peterson, Eric D. / Relation of Patient Age and Mortality to Reported Contraindications to Early Beta-Blocker Use for Non-ST-Elevation Acute Coronary Syndrome. In: American Journal of Cardiology. 2009 ; Vol. 104, No. 10. pp. 1324-1329.
@article{67996b51d2a144a8a65ba1059a00424b,
title = "Relation of Patient Age and Mortality to Reported Contraindications to Early Beta-Blocker Use for Non-ST-Elevation Acute Coronary Syndrome",
abstract = "We evaluated the reported contraindications to early β-blocker use and associated mortality within and across patient age groups. Contraindications to early β-blocker use were evaluated in patients with non-ST-elevation acute coronary syndrome in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) initiative from February 2003 to December 2006. The prevalence, reasons, and trends in the contraindications were evaluated by age (≤65, 66 to 74, and ≥75 years). The associations between the reported contraindications and in-hospital mortality were determined within and compared across age groups using the logistic generalized estimating equations method, adjusting for baseline patient characteristics. Of 112,448 patients, 11,711 (10.4{\%}) had a reported contraindication to early β-blocker use. The prevalence varied by age (≤65, 7.9{\%}; 66 to 74, 10.6{\%}; and ≥75, 13.4{\%}; p <0.0001). No significant changes were seen over time, except for a small increase in patients ≤65 years (p = 0.001). Among the hospitals with >40 patients in the registry, the median hospital level rate of reported contraindications was 9.9{\%} (interquartile range 6.7{\%} to 14.3{\%}). The distribution of rates was more widespread among the hospitals' older versus younger patients. In all age groups, a statistically significant greater association was found with in-hospital mortality in those with reported contraindications versus those without contraindications who received a β blocker (adjusted odds ratio 2.81, 95{\%} confidence interval 2.28 to 3.46; adjusted odds ratio 2.50, 95{\%} confidence interval 2.07 to 3.03; adjusted odds ratio 2.11, 95{\%} confidence interval 1.88 to 2.37, for ages ≤65, 66 to 74, and ≥75 years, respectively). The strength of the association was similar across all age groups (interaction p = 0.19). The reported contraindications to early β-blocker use were common and increased with age. The contraindications were independently associated with greater in-hospital mortality, underscoring the importance of accurately identifying contraindications. In conclusion, the results did not indicate any disparity in reporting the contraindications according to patient age.",
author = "{Allen LaPointe}, {Nancy M.} and Chen, {Anita Y.} and Roe, {Matthew T.} and Cohen, {David J.} and Diercks, {Deborah B.} and Hoekstra, {James W.} and Fesmire, {Francis M.} and Gibler, {W. Brian} and Ohman, {E. Magnus} and Peterson, {Eric D.}",
year = "2009",
month = "11",
day = "15",
doi = "10.1016/j.amjcard.2009.06.054",
language = "English (US)",
volume = "104",
pages = "1324--1329",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Relation of Patient Age and Mortality to Reported Contraindications to Early Beta-Blocker Use for Non-ST-Elevation Acute Coronary Syndrome

AU - Allen LaPointe, Nancy M.

AU - Chen, Anita Y.

AU - Roe, Matthew T.

AU - Cohen, David J.

AU - Diercks, Deborah B.

AU - Hoekstra, James W.

AU - Fesmire, Francis M.

AU - Gibler, W. Brian

AU - Ohman, E. Magnus

AU - Peterson, Eric D.

PY - 2009/11/15

Y1 - 2009/11/15

N2 - We evaluated the reported contraindications to early β-blocker use and associated mortality within and across patient age groups. Contraindications to early β-blocker use were evaluated in patients with non-ST-elevation acute coronary syndrome in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) initiative from February 2003 to December 2006. The prevalence, reasons, and trends in the contraindications were evaluated by age (≤65, 66 to 74, and ≥75 years). The associations between the reported contraindications and in-hospital mortality were determined within and compared across age groups using the logistic generalized estimating equations method, adjusting for baseline patient characteristics. Of 112,448 patients, 11,711 (10.4%) had a reported contraindication to early β-blocker use. The prevalence varied by age (≤65, 7.9%; 66 to 74, 10.6%; and ≥75, 13.4%; p <0.0001). No significant changes were seen over time, except for a small increase in patients ≤65 years (p = 0.001). Among the hospitals with >40 patients in the registry, the median hospital level rate of reported contraindications was 9.9% (interquartile range 6.7% to 14.3%). The distribution of rates was more widespread among the hospitals' older versus younger patients. In all age groups, a statistically significant greater association was found with in-hospital mortality in those with reported contraindications versus those without contraindications who received a β blocker (adjusted odds ratio 2.81, 95% confidence interval 2.28 to 3.46; adjusted odds ratio 2.50, 95% confidence interval 2.07 to 3.03; adjusted odds ratio 2.11, 95% confidence interval 1.88 to 2.37, for ages ≤65, 66 to 74, and ≥75 years, respectively). The strength of the association was similar across all age groups (interaction p = 0.19). The reported contraindications to early β-blocker use were common and increased with age. The contraindications were independently associated with greater in-hospital mortality, underscoring the importance of accurately identifying contraindications. In conclusion, the results did not indicate any disparity in reporting the contraindications according to patient age.

AB - We evaluated the reported contraindications to early β-blocker use and associated mortality within and across patient age groups. Contraindications to early β-blocker use were evaluated in patients with non-ST-elevation acute coronary syndrome in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) initiative from February 2003 to December 2006. The prevalence, reasons, and trends in the contraindications were evaluated by age (≤65, 66 to 74, and ≥75 years). The associations between the reported contraindications and in-hospital mortality were determined within and compared across age groups using the logistic generalized estimating equations method, adjusting for baseline patient characteristics. Of 112,448 patients, 11,711 (10.4%) had a reported contraindication to early β-blocker use. The prevalence varied by age (≤65, 7.9%; 66 to 74, 10.6%; and ≥75, 13.4%; p <0.0001). No significant changes were seen over time, except for a small increase in patients ≤65 years (p = 0.001). Among the hospitals with >40 patients in the registry, the median hospital level rate of reported contraindications was 9.9% (interquartile range 6.7% to 14.3%). The distribution of rates was more widespread among the hospitals' older versus younger patients. In all age groups, a statistically significant greater association was found with in-hospital mortality in those with reported contraindications versus those without contraindications who received a β blocker (adjusted odds ratio 2.81, 95% confidence interval 2.28 to 3.46; adjusted odds ratio 2.50, 95% confidence interval 2.07 to 3.03; adjusted odds ratio 2.11, 95% confidence interval 1.88 to 2.37, for ages ≤65, 66 to 74, and ≥75 years, respectively). The strength of the association was similar across all age groups (interaction p = 0.19). The reported contraindications to early β-blocker use were common and increased with age. The contraindications were independently associated with greater in-hospital mortality, underscoring the importance of accurately identifying contraindications. In conclusion, the results did not indicate any disparity in reporting the contraindications according to patient age.

UR - http://www.scopus.com/inward/record.url?scp=71749085084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71749085084&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2009.06.054

DO - 10.1016/j.amjcard.2009.06.054

M3 - Article

C2 - 19892045

AN - SCOPUS:71749085084

VL - 104

SP - 1324

EP - 1329

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 10

ER -